Introduction {#Sec1}
============

Achieving good glycemic control in efforts to prevent disease complications is the primary goal in the treatment of type 1 and type 2 diabetes \[[@CR1]\]. Diabetes care guidelines and product labeling for current basal insulin analogs recommend regular blood glucose self-measurement \[[@CR1]--[@CR6]\] to help people with diabetes maintain appropriate glycemic control and become more actively involved in their healthcare \[[@CR7]--[@CR9]\]. Insulin dose is also typically determined and titrated up or down as needed according to algorithms based on blood glucose results \[[@CR1]\]. However, challenges exist that can prevent the achievement of glycemic targets with insulin, including perceptions on the part of patients and healthcare providers (HCPs) that insulin therapy can be burdensome or too complex to manage \[[@CR10], [@CR11]\]. Patients who take an active role in the management of their diabetes and titration of their insulin may feel more empowered to take charge of their self-care and have a stronger belief that their actions can influence their disease, thus leading to better treatment outcomes \[[@CR12]--[@CR14]\]. In determining how self-care can best be facilitated for patients with diabetes, the cost and burden of frequent glucose testing must be considered when designing treatment plans, as these can be significant factors when added to the health, quality of life (QoL), and financial toll of poorly controlled diabetes.

Numerous studies investigating the cost of self-measured blood glucose (SMBG) testing have found that it comprises a substantial portion of diabetes-related expenditures \[[@CR15]--[@CR18]\]. In a retrospective database analysis in the US that included more than 45,000 patients, testing accounted for 27% of diabetes care costs: total combined blood glucose testing and insulin-related costs were \$2,850 USD/patient/year, with \$772 USD/patient/year attributed to blood glucose testing alone \[[@CR18]\]. In other countries, testing comprises an even higher percentage of diabetes care costs (e.g., 40% in Canada \[[@CR16], [@CR17]\] and 42% in Germany \[[@CR15]\]).

Insulin degludec (IDeg) is a new basal insulin (currently approved in Europe, Japan, Mexico and several other countries) with a flat, ultra-long action profile that may enable subjects to achieve glycosylated hemoglobin (HbA~1c~) levels closer to glycemic target with fewer hypoglycemic episodes \[[@CR19]--[@CR21]\]. It was thus hypothesized that IDeg could be titrated once-weekly based on a single pre-breakfast SMBG value, offering a simple, patient-focused titration algorithm that would encourage self-titration, enhancing patient empowerment as well as substantially reducing treatment costs by reducing the frequency of blood glucose measurements required for dose adjustments. In this study, after 26 weeks of treatment, the authors compared the efficacy and safety of two different self-titration algorithms for IDeg administered once-daily (OD) plus metformin, in insulin-naïve subjects with type 2 diabetes: a "Simple" algorithm, in which 4 unit (U) dose adjustments were made based on a single pre-breakfast SMBG measurement was compared with a "Step-wise" algorithm, in which dose adjustments were made in increments of 2 U (Table [1](#Tab1){ref-type="table"}) based on the lowest of three consecutive pre-breakfast SMBG readings. In both groups, IDeg was adjusted once-weekly. The objective of this trial was to provide additional guidance on the use of IDeg in clinical practice by investigating whether good glycemic control could be attained with a more simplified titration schedule, involving fewer SMBG tests, than that previously employed during the IDeg Phase 3a development program.Table 1Comparison of BEGIN^®^ Once Simple titration algorithmsPre-breakfast SMBGDose adjustment IDeg Simple^a^Dose adjustment IDeg Step-wise^b^mmol/Lmg/dLUU\<3.1\<56−4−43.1--3.956--70−24.0--5.071--90005.1--7.091--126+4+27.1--8.0127--144+48.1--9.0145--162+6\>9.0\>162+8*IDeg* insulin degludec, *SMBG* self-measured blood glucose^a^Based on a single measurement on the day of titration^b^Based on the lowest of 3 consecutive days' measurements

Methods {#Sec2}
=======

The study was conducted according to the Declaration of Helsinki, as revised in 2000 and 2008 \[[@CR22]\] and ICH Good Clinical Practice (1996) guidelines \[[@CR23]\], with prior approval by appropriate ethics committees and patient consent obtained in writing prior to the start of any study-related activities. Eligible participants included insulin-naïve men or women ≥18 years of age, with type 2 diabetes, HbA~1c~ 7.0--10.0% (inclusive), and body mass index (BMI) ≤45.0 kg/m^2^, who were treated with ≥1,000 mg/day metformin alone or in combination with one or two other oral antidiabetic medications (OADs) \[including a sulfonylurea (SU) or Glinide, dipeptidyl peptidase-4 (DPP-4) inhibitors, α-glucosidase inhibitors or thiazolidinediones (TZDs)\], with unchanged dosing for ≥12 weeks prior to randomization. Participants were ineligible if they had used a glucagon-like peptide-1 (GLP-1) receptor agonist within 12 weeks prior to randomization, had initiated or significantly changed treatment that could interfere with glucose metabolism, had significant disease other than type 2 diabetes, were pregnant or breastfeeding, or had recurrent severe hypoglycemia or hypoglycemia unawareness. Subjects could be withdrawn from the trial due to withdrawal of consent, not fulfilling inclusion/exclusion criteria (randomized in error), non-compliance, or at the discretion of the investigator due to a safety concern. Subjects who were withdrawn after randomization were not to be replaced.

Study Design and Treatment {#Sec3}
--------------------------

This was a multinational (conducted in the US, Spain, Finland, and Germany), Phase 3b, multi-center, two-armed, parallel group, open-label, randomized, treat-to-target study that compared the efficacy and safety of IDeg OD (IDeg 100 U/mL, FlexTouch^®^ pen, Novo Nordisk A/S, Bagsværd, Denmark), adjusted using two different titration algorithms in combination with metformin. The trial consisted of a 26-week period; total study duration was \~28 weeks (including 1 week for screening and a 7-day follow-up period). After discontinuing all OADs other than metformin, subjects were randomized 1:1 by an interactive voice/web response system (IV/WRS) to IDeg~Simple~ or IDeg~Step-wise~ insulin self-titration algorithms, as defined below. Subjects were instructed to self-titrate in accordance with their respective algorithms and continue with their pre-trial metformin dose. At randomization, week 4, and week 12, subjects in both treatment arms received diet and exercise counselling by an HCP. The importance of maintaining a healthy diet and exercise plan was reinforced at each visit.

A Novo Nordisk A/S safety committee blinded to treatment performed on-going safety surveillance, but could request unblinding of the data to be performed by an independent ad hoc group, if needed. An external cardiovascular adjudication committee was masked to treatment. Blinded insulin titration surveillance was performed by Novo Nordisk A/S.

Insulin degludec was administered OD at a starting dose of 10 U in both groups. Variation of injection time from day to day was permitted, as long as subjects maintained a minimum of 8 and a maximum of 40 h between injections. Self-adjustment of IDeg dose was to be performed once-weekly in both groups according to the algorithms outlined in Table [1](#Tab1){ref-type="table"}. In the IDeg~Simple~ arm, dose adjustment was based on a single pre-breakfast SMBG measurement. In the IDeg~Step-wise~ arm, dose adjustment was based on the lowest of 3 consecutive days' pre-breakfast SMBG measurements.

Efficacy and Safety Assessments {#Sec4}
-------------------------------

HbA~1c~ was analyzed using a Bio-Rad high-performance liquid chromatography method at Visits 1 (screening), 2 (randomization), 14 (week 12), and 28 (week 26). Fasting plasma glucose (FPG) blood samples were assayed using a hexokinase-UV method at Visits 2, 14, and 28. At the first visit, subjects were provided with a glucose meter for SMBG measurement and instructions for use; blood glucose was measured with test strips calibrated to plasma glucose (PG) to obtain PG-equivalent values presented in this report. Subjects performed SMBG measurements before breakfast weekly after randomization and also performed an 8-point SMBG profile prior to Visits 2, 14, and 28.

Adverse events (AEs) and hypoglycemic episodes were documented throughout the study, with confirmed hypoglycemia defined as episodes of severe hypoglycemia (requiring assistance from another person) and episodes with PG value \<3.1 mmol/L (56 mg/dL). Confirmed nocturnal hypoglycemic episodes were those occurring between 0001 and 0559 hours (inclusive). Laboratory safety variables, insulin dose, and body weight were recorded at pre-specified intervals. Two patient-reported outcome (PRO) questionnaires (Device-Specific questionnaires I and II) were self-completed at Visits 14 and 28 to assess subject satisfaction with the FlexTouch pen as an additional trial endpoint. The PRO questionnaire utilized here to assess patient satisfaction with FlexTouch had previously been used in other trials to assess satisfaction with the FlexPen^®^ device (Novo Nordisk A/S, Bagsværd, Denmark) \[[@CR24], [@CR25]\].

Statistical Methods {#Sec5}
-------------------

With 218 subjects, there was 85% power to demonstrate non-inferiority at 0.4% in evaluation of the per-protocol (PP) analysis set (defined as all subjects without major protocol violations who were exposed to treatment for \>12 weeks and who had a valid assessment necessary for deriving the primary endpoint), accounting for an anticipated total of 15% that would not be included in the PP analysis set. Sample size was determined using a *t*-statistic under the assumption of a one-sided test of size 2.5% and a zero mean treatment difference. Data were reported using a 95% CI and *P* values for one-sided testing for non-inferiority at alpha = 0.025 for the primary analysis, and two-sided testing with alpha = 0.050 for all other analyses. Statistical analyses of all efficacy and patient-reported outcome endpoints were based on the full analysis set (FAS), defined as all randomized subjects, and followed the intention-to-treat (ITT) principle unless otherwise noted. The robustness of the results for change in HbA~1c~ was explored by an additional analysis of the PP analysis set. Further, robustness was explored by an additional analysis of the set of all subjects who completed the trial and by using a simple model based on the FAS with only treatment and baseline HbA~1c~ as covariates. Safety endpoints were summarized based on the safety analysis set (SAS), defined as all subjects who received at least one dose of IDeg, and analyzed based on the FAS. Statistical analyses were performed using SAS^®^ 9.1.3 software (SAS Institute Inc., Cary, NC, USA).

Change from baseline in HbA~1c~ after 26 weeks was analyzed using an analysis of variance (ANOVA) method with treatment, region, sex, and antidiabetic therapy at screening as fixed factors, and age and baseline HbA~1c~ as covariates. Non-inferiority was considered confirmed if the upper bound of the two-sided 95% CI for the treatment difference (IDeg~Simple~ − IDeg~Step-wise~) for the mean change in HbA~1c~ was ≤0.4%. Change in FPG and change in body weight were analyzed using an ANOVA model similar to that used for the primary analysis, but with the relevant baseline value as covariate for each measure. Responder endpoints (proportion of subjects who achieved target HbA~1c~ and proportion who achieved target without hypoglycemia) were analyzed using a logistic regression model with the same factors and covariates as those used for the primary analysis. An 8-point SMBG profile included measurements before and 90 min after the start of breakfast, lunch and main evening meal, prior to bedtime, and before breakfast the following day. A mixed effect model including treatment, time, interaction between treatment and time, antidiabetic therapy at screening, sex and region as fixed factors, age as covariate and subject as random effect was fitted to the 8-point SMBG profile data. From this model, mean profile by treatment and relevant treatment differences were estimated and explored. Treatment-emergent AEs, hypoglycemic episodes, laboratory parameters, physical examination, electrocardiogram (ECG), fundoscopy/fundusphotography, vital signs, PRO (Device-Specific questionnaires I and II) and insulin dose were summarized with descriptive statistics. The numbers of treatment-emergent confirmed and nocturnal confirmed hypoglycemic episodes were analyzed using a negative binomial regression model with a log-link function and the logarithm of the time period for which a hypoglycemic episode was considered treatment emergent as offset; the model included treatment, sex, region, and antidiabetic treatment at screening as fixed factors and age as covariate.

Results {#Sec6}
=======

Participants were allocated 1:1 to the IDeg~Simple~ (*n* = 111) and IDeg~Step-wise~ (*n* = 111) arms (Table [2](#Tab2){ref-type="table"}). Of 222 randomized participants, 221 (99.5%) received trial drug. Treatment arms were well matched at baseline, with the exception of a slightly higher mean body weight and more female subjects in the IDeg~Simple~ arm. The majority of subjects were white \[89.2% (IDeg~Simple~) and 87.4% (IDeg~Step-wise~)\]. Subjects in the IDeg~Step-wise~ arm had a slightly longer mean duration of diabetes. The majority of participants in both groups were taking two OADs at baseline (61/111 subjects, 55%); \~21% in each group were taking \>2 OADs, and \~24% in each group were taking 1 OAD. The most common pre-trial OAD other than metformin was a SU. Most \[89.2% (99/111), IDeg~Simple~; 88.3% (98/111), IDeg~Step-wise~\] subjects completed the trial. Four IDeg~Simple~ and three IDeg~Step-wise~ subjects were withdrawn due to AEs; five IDeg~Simple~ and seven IDeg~Step-wise~ subjects were withdrawn due to meeting withdrawal criteria; and three subjects in each group were withdrawn due to reasons classified as "other" (Fig. [1](#Fig1){ref-type="fig"}).Table 2Demographics and baseline characteristicsCharacteristicIDeg SimpleIDeg Step-wiseParticipants in the full analysis set, *n*111111Participants in the safety analysis set, *n*110111Female/male, *n* (%)43 (38.7)/68 (61.3)36 (32.4)/75 (67.6)Ethnic group: White/Black/Asian, American Indian or Alaska native/other, *n* (%)99 (89.2)/8 (7.2)/3 (2.7)/1 (0.9)97 (87.4)/9 (8.1)/2 (1.8)/3 (2.7)Age (years)59.4 (±9.5)58.5 (±11.1)Body weight (kg)95.7 (±18.9)91.3 (±18.2)Body mass index (kg/m^2^)33.4 (±5.8)31.5 (±5.2)Duration of diabetes (years)8.9 (±5.5)9.6 (±7.2)HbA~1c~ (%)8.1 (±0.9)8.2 (±0.9)FPG mmol/L9.3 (±2.6)9.4 (±2.8) mg/dL167.4 (±46.8)169.2 (±50.4)OAD treatment at screening, *n* (%) 1 OAD27 (24.3)26 (23.4)  Met27 (24.3)26 (23.4) 2 OADs61 (55.0)61 (55.0)  Met + DPP-4I16 (14.4)13 (11.7)  Met + Glinide1 (0.9)2 (1.8)  Met + SU40 (36.0)42 (37.8)  Met + TZD4 (3.6)4 (3.6) 3 OADs23 (20.7)24 (21.6)  α-glu inhib + Met + DPP-4I1 (0.9)--  Met + DPP-4I + Glinide1 (0.9)3 (2.7)  Met + DPP-4I + SU13 (11.7)8 (7.2)  Met + DPP-4I + TZD--2 (1.8)  Met + SU + TZD8 (7.2)11 (9.9)Data are presented as number (%) or mean (SD)*OAD* oral antidiabetic drug, *Met* metformin, *SU* sulfonylurea, *TZD* thiazolidinedione, *DPP*-*4I* dipeptidyl peptidase 4 inhibitor, α-*glu inhib*, alpha-glucosidase inhibitor, *FPG* fasting plasma glucose, *IDeg* insulin degludec, *SD* standard deviation, *HbA* ~*1c*~ glycosylated hemoglobinFig. 1BEGIN Once Simple participant flow. \*IDeg~Simple~: arthralgia and blurred vision (1 subject); toxicity to various agents (1 subject); astrocytoma (1 subject); acute myocardial infarction (1 subject). IDeg~Step-wise~: liver metastases (1 subject); intervertebral disc protrusion (1 subject); worsening of type 2 diabetes/vitamin D deficiency/anterior pituitary disorder/depression (1 subject). ^†^IDeg~Simple~: withdrawal of consent (2 subjects), investigator decision to withdraw subject due to safety or non-compliance (2 subjects), randomized in error (1 subject). IDeg~Step-wise~: withdrawal of consent (2 subjects), investigator decision to withdraw subject due to safety or non-compliance (1 subject), randomized in error (4 subjects). ^‡^IDeg~Simple~: lost to follow-up (2 subjects) and withdrawn after 11.7 weeks of treatment due to HbA~1c~ increased (1 subject) IDeg~Step-wise~: lost to follow-up (3 subjects).*AE* adverse event,*FAS* full analysis set,*IDeg* insulin degludec,*SAS* safety analysis set

HbA~1c~ decreased from baseline to week 26 in both groups; −1.09% with IDeg~Simple~, to 7.0%, and −0.93% with IDeg~Step-wise~, to 7.2% (Fig. [2](#Fig2){ref-type="fig"}a). IDeg~Simple~ was non-inferior to IDeg~Step-wise~ in lowering HbA~1c~, as the upper limit of the 95% CI for the estimated treatment difference (ETD) was \<0.4%: ETD (IDeg~Simple~ − IDeg~Step-wise~) −0.16%-points (−0.39; 0.07)~95%\ CI~. Analyses to measure robustness of results were consistent with FAS results. Significantly more IDeg~Simple~ \[56.8% (63/111)\] than IDeg~Step-wise~ \[41.4% (46/111)\] subjects achieved HbA~1c~ \<7.0% at end-of-trial; estimated odds ratio (IDeg~Simple~/IDeg~Step-wise~): 1.93 (1.04; 3.55)~95%\ CI~ (*P* = 0.0356). There was no significant difference in the proportion of patients achieving HbA~1c~ \<7% without confirmed hypoglycemia \[40.6% (43/106) IDeg~Simple~; 34.6% (36/104) IDeg~Step-wise~\]; estimated odds ratio (IDeg~Simple~/IDeg~Step-wise~): 1.26 (0.69; 2.29)~95%\ CI~.Fig. 2BEGIN Once Simple glycemic efficacy: **a** mean HbA~1c~ over time; **b** mean FPG ± SEM over time; **c** 8-point SMBG profile at baseline and week 26. *BF* breakfast, *FAS* full analysis set, *FPG* fasting plasma glucose, *IDeg* insulin degludec, *HbA* ~*1c*~ glycosylated hemoglobin, *SEM* standard error of the mean, *SMBG* self-measured blood glucose

Fasting plasma glucose decreased from baseline to week 26 by 3.27 mmol/L with IDeg~Simple~, to 6.1 mmol/L, and by 2.68 mmol/L with IDeg~Step-wise~, to 6.8 mmol/L (Fig. [2](#Fig2){ref-type="fig"}b). No significant difference was seen between groups: ETD (IDeg~Simple~ − IDeg~Step-wise~: −0.57 mmol/L (−1.30; 0.17)~95%\ CI~. The most pronounced decline in FPG occurred during the first 12 weeks. No difference between groups in 8-point SMBG profiles was seen at any of the eight measured time points at baseline or at end-of-trial (Fig. [2](#Fig2){ref-type="fig"}c).

Rates of confirmed hypoglycemia were low, at 1.60 and 1.17 events per patient year of exposure (PYE) with IDeg~Simple~ and IDeg~Step-wise~, respectively (Fig. [3](#Fig3){ref-type="fig"}a), with no significant difference between groups (*P* = 0.4273). One severe hypoglycemic episode occurred in the IDeg~Simple~ arm 5 days after the last treatment with IDeg. Observed rates of nocturnal confirmed hypoglycemia were very low at 0.21 (IDeg~Simple~) and 0.10 (IDeg~Step-wise~) events per PYE (Fig. [3](#Fig3){ref-type="fig"}b), with no significant difference between groups (*P* = 0.2047).Fig. 3Hypoglycemia rate (IDeg) in the BEGIN Type 2 diabetes trials: **a** confirmed hypoglycemia, **b** nocturnal confirmed hypoglycemia. Data from this trial shown by light blue bars. Rate (events/patient year of exposure) is at end-of-trial and based on SAS. *IDeg* insulin degludec, *PYE* patient year of exposure, *SAS* statistical analysis set

The observed daily insulin dose after 26 weeks was 62 U (0.61 U/kg) in the IDeg~Simple~ arm and 48 U (0.50 U/kg) in the IDeg~Step-wise~ arm. Up to week 4, mean doses were similar, after which the mean dose in the Simple arm was higher. The increase in IDeg dose per week began to level off in the IDeg~Step-wise~ arm at week 14. Although subjects were permitted to adjust their dose by increments larger than 4 U in the IDeg~Step-wise~ arm, the mean weekly incremental increase was ≤3 U.

Mean baseline body weight was higher in the IDeg~Simple~ arm (95.7 kg) than in the IDeg~Step-wise~ arm (91.3 kg). Modest increases in weight were observed from baseline to week 26 in both groups: IDeg~Simple~: (+1.6 kg, to mean weight 97.3 kg at week 26), IDeg~Step-wise~ (+1.1 kg, to mean weight 92.4 kg at week 26), with no statistically significant difference in weight change: ETD (IDeg~Simple~ − IDeg~Step-wise~) 0.46 kg (−0.35; 1.26)~95%\ CI~. There were no clinically relevant differences from baseline to end-of-trial or between treatment arms in vital signs, ECG, fundoscopy, physical examination or laboratory parameters (data not shown).

No safety concerns were raised during this trial. Please see Table [3](#Tab3){ref-type="table"} for an overview of the rates of AEs and serious AEs (SAEs) reported. AEs and SAEs were distributed similarly between groups. Most AEs were of mild or moderate severity and the rates of AEs classified as possibly or probably related to trial product by the investigator were low \[10.0% (IDeg~Simple~); 7.2% (IDeg~Step-wise~)\]. Injection-site reactions (ISRs) were reported by 2.7% (3 subjects with 3 events) of IDeg~Simple~ and 4.5% (5 subjects with 16 events) of IDeg~Step-wise~ subjects; one subject reported 9 of the 16 total events in the IDeg~Step-wise~ arm, and reported "pain" as the ninth ISR. No SAEs were reported in ≥5% of subjects and none were considered by the investigator to be related to trial product. One death occurred in this study 154 days after starting trial drug in an IDeg~Step-wise~-treated participant, due to liver metastasis (the primary cancer was reported as probable small cell lung carcinoma). The event was considered by the investigator to be unlikely related to treatment. One other SAE neoplasm event \[astrocytoma (IDeg~Simple~)\], and three events adjudicated as major adverse cardiovascular events \[coronary artery stenosis (IDeg~Simple~), acute myocardial infarction (IDeg~Simple~) and coronary artery occlusion (IDeg~Step-wise~)\] occurred, all of which were considered by the investigator to be unlikely related to treatment. No IDeg-related medication errors were reported.Table 3Summary of adverse eventsIDeg Simple (*n* = 110)IDeg Step-wise (*n* = 111)*n*%*ERn*%*ER*AEs6660.01813466962.2197379AEs occurring with a frequency ≥5%1715.518341412.62242Headache87.381587.21427Nasopharyngitis109.1101976.3815SAEs54.581576.3815Treatment-emergent events occurring after first exposure and no later than 7 days after last exposure. Safety analysis set. *n* number of patients with events, *%* proportion of patients with events, *E* number of events, *R* number of events per 100 patient-years

In the Device-Specific questionnaires, designed to assess satisfaction with the insulin delivery device, more than 90% of subjects at week 12 and week 26 indicated the highest levels of satisfaction (response category 1 or 2) with FlexTouch in categories such as confidence in using the pen, ease in learning to use the device, ease in holding the pen stable or seeing the dose scale while injecting, pushing down the injection button and selecting the correct dose. At 26 weeks, 98% of subjects reported no problems using FlexTouch and 100% of subjects indicated that they would recommend the pen. Please refer to Table [4](#Tab4){ref-type="table"} for additional details on the results of the questionnaires (Table [4](#Tab4){ref-type="table"} contains a subset of the total questions surveyed in this trial).Table 4Device-Specific questionnaire responsesPositive response (Category 1 or 2)^a^Neutral or negative response (Category 3, 4 or 5)^a^*n* (%)*n* (%)1. How easy or difficult do you find it to hold the pen stable when injecting? Wk 12195 (94.7)11 (5.3) Wk 26202 (98.5)3 (1.5)2. How easy or difficult is it to push down the injection button? Wk 12197 (95.2)9 (4.8) Wk 26202 (98.0)4 (2.0)3. How easy or difficult is it to turn the dose selector when choosing the right dose? Wk 12199 (97.5)5 (2.5) Wk 26196 (96.1)8 (3.9)4. How easy or difficult is it to know if the push button has been pushed down completely? Wk 12192 (93.2)14 (6.8) Wk 26195 (95.2)9 (4.8)5. How easy or difficult is it to see the dose scale when injecting? Wk 12176 (85.5)30 (14.5) Wk 26174 (85.2)30 (14.8)6. How easy or difficult was it to learn how to use this pen? Wk 12200 (98.0)4 (2.0) Wk 26199 (98.5)3 (1.5)7. How easy or difficult is it to inject your usual insulin dose? Wk 12193 (94.6)11 (5.4) Wk 26196 (97.0)6 (3.0)8. How easy or difficult is it to reach the dose button when injecting your insulin dose? Wk 12193 (94.6)11 (5.4) Wk 26195 (96.5)7 (3.5)9. Overall, how confident are you in your management of daily insulin injection using this pen? Wk 12191 (93.1)14 (6.9) Wk 26196 (96.1)8 (3.9)10. Overall, how confident are you in controlling your blood sugar level using this pen? Wk 12167 (81.8)37 (18.2) Wk 26178 (88.6)23 (11.4)Positive response^b^Negative response^b^*n* (%)*n* (%)1. Did you have any problems using the pen? Wk 12205 (100.0)N/A Wk 26201 (100.0)N/A2. Would you recommend the pen? Wk 12202 (100.0)N/A Wk 26200 (100.0)N/A^a^Data is based on FAS and summarized independent of treatment arm. *%* percentage based on ITT population who answered the questionnaire. Categories for questions 1--8: *1* very easy, *2* somewhat easy, *3* neither easy nor difficult, *4* somewhat difficult, *5* very difficult. Categories for questions 9--10: *1* very, *2* quite, *3* somewhat, *4* not very, *5* not at all (confident). *N* number, *Wk* week, *ITT* intention-to-treat^b^Data is based on FAS and summarized independent of treatment arm. Categories for questions 1--2: *1* no, *2* yes. *N* number, *Wk* week, *NA* not applicable, *ITT* intention-to-treat

Discussion {#Sec7}
==========

Both the Simple and Step-wise titration algorithms were effective, well-tolerated methods of achieving glycemic targets with IDeg, thereby demonstrating that titration based on either a single weekly SMBG measurement with the Simple algorithm, or three measurements with the Step-wise algorithm, provide suitable options for patients with type 2 diabetes. Titration using the Simple algorithm was shown to be non-inferior to titration using the Step-wise algorithm in terms of improving HbA~1c~ and both methods resulted in a similar FPG reduction. End-of-trial HbA~1c~ and change from baseline in HbA~1c~ in both treatment arms were similar to values seen with IDeg in similar previous Phase 3a (BEGIN) trials in people with type 2 diabetes \[[@CR26]--[@CR29]\]. These previous trials all demonstrated similar efficacy between IDeg and insulin glargine as demonstrated by non-inferiority in terms of change in HbA~1c~, were 26 or 52 weeks in duration, enrolled insulin-naïve subjects (except for the BEGIN Basal--Bolus T2 study in which insulin aspart was dosed with meals \[[@CR26]\]) and employed a titration algorithm similar to the Step-wise algorithm, but with weekly titration based on the mean of three consecutive days' pre-breakfast SMBG measurements \[[@CR26]--[@CR29]\].

IDeg dose was increased more quickly in the IDeg Simple arm, whereas insulin dose escalation was reduced earlier in the IDeg~Step-wise~ arm, reflecting a point of differentiation between the algorithms: as pre-breakfast SMBG values approached target, the Step-wise algorithm permitted a smaller dose increase of 2 U versus the recommended 4 U increase in the IDeg~Simple~ arm. Insulin dose was higher at end-of-trial in the IDeg~Simple~ arm than in the IDeg~Step-wise~ arm, which may account for the non-significant differences seen between groups in FPG and hypoglycemia. FPG values were numerically lower over longer periods of time in the IDeg Simple arm; this may have influenced the observed rates of hypoglycemia, as these rates represented the entire treatment period. The small and non-significant difference in FPG between the IDeg~Simple~ and IDeg~Step-wise~ arms likely also contributed to the difference between groups in achieving the HbA~1c~ target of \<7%. It is important to note that there was no significant difference between groups in the achievement of the HbA~1c~ target without confirmed hypoglycemia.

The Simple algorithm offers an easy and patient-friendly way to titrate IDeg; in addition, the capacity to adjust IDeg doses with a 4 U increase or decrease, based on a single weekly SMBG value, may substantially reduce the financial and time burden and inconvenience of titration measurements. Incidence rates of hypoglycemic episodes were very low, with no significant difference between the Simple and Step-wise arms. As shown in Fig. [3](#Fig3){ref-type="fig"}a and b, respectively, end-of-trial confirmed and nocturnal confirmed hypoglycemia rates seen here were comparable to or lower than rates with IDeg administered OD in the BEGIN trials in people with type 2 diabetes; rates that, in turn, were lower than or similar to those seen with comparator insulin glargine in other studies of the insulin degludec development program \[[@CR26]--[@CR29]\].

Subjects in both treatment arms adhered closely to their respective algorithms. The ability and willingness of patients to adhere to a given treatment regimen is an important component in the success of insulin therapy. Surveys of physicians and patients have identified "too busy" and "complicated regimen" as prominent reasons why patients miss or omit insulin injections; 17% of patients report difficulty in adjusting insulin doses, and 60% of patients feel that their insulin regimens can be restrictive \[[@CR10], [@CR11]\]. There is evidence to support the premise that if patients are more comfortable with, and accepting of, their dosing regimen, they may be more willing to continue treatment in the long-term \[[@CR12]--[@CR14]\]. Furthermore, patient empowerment may be enhanced by a titration algorithm that facilitates self-adjustment of basal insulin and better adherence to treatment regimens, potentially leading to improved health outcomes. In the Predictable Results and Experience in Diabetes through Intensification and Control to Target: An International Variability Evaluation (PREDICTIVE) 303 study with insulin detemir \[[@CR4]\], a simplified self-adjusted dosing algorithm in which patients tested SMBG daily and adjusted their dose every 3 days based on the mean of the previous 3 days' values was shown to significantly lower HbA~1c~ versus standard-of-care, physician-driven adjustments over a period of 6 months \[[@CR4]\], thus, providing further evidence that a simple self-titration method can help subjects achieve glycemic targets. The efficacy and safety of insulin self-titration has likewise been demonstrated with additional studies with insulin detemir \[[@CR30]\] and with insulin glargine \[[@CR31]--[@CR33]\], in which subjects experienced reductions in HbA~1c~ with a good safety profile when self-adjusting doses using trial-specified algorithms. In addition, patient acceptance of the insulin delivery device used to administer doses is a factor that appears to influence adherence and persistence with a given treatment regimen \[[@CR34]--[@CR37]\]. It has been reported that positive perceptions of convenience also play an important role in the persistence of pen use \[[@CR38]\]. In this trial, although it was not designed to compare methods of insulin administration, high levels of satisfaction with the FlexTouch insulin pen device were reported in both treatment arms and all subjects indicated that they would recommend the pen to others. This reflects the experiences of patients in other IDeg trials using the same device, in which the majority of patients reported ease in using the pen and a high degree of satisfaction with FlexTouch \[[@CR39]--[@CR43]\].

In this study, insulin degludec was used in both arms of the trial. The effectiveness and safety of the two titration algorithms used with insulin degludec may not apply to treatment and decision-making with other basal insulins. This could represent a limitation of the study. Moreover, the open-label nature of the study could impact the results. Patients using the Simple algorithm may have found this algorithm easier to use. However, as patients in both arms adhered very closely to their treatment algorithms and efficacy and safety in both arms were comparable, there was no evidence to support that this potential bias impacted results. A longer-term study further exploring the Simple algorithm may be useful to determine the impact, if any, of a simpler titration algorithm on patient adherence to treatment and, ultimately, efficacy and safety outcomes.

Conclusion {#Sec8}
==========

Achieving good glycemic control in patients with type 2 diabetes is an important way to prevent or limit diabetes complications, and control the costs of intensified healthcare utilization stemming from these complications. SMBG is an integral part of effective diabetes management; however, glucose meters, test strips, lancets, and alcohol wipes are consumable items that comprise on-going expenses, with test strips identified as a major driver of these costs \[[@CR15]--[@CR18]\]. New medications and treatment regimens that permit a reduction in the number of SMBG measurements without compromising clinical outcomes would likely benefit all basal insulin-treated patients who may find current algorithms confusing or cumbersome. These patients may be more likely to adhere to a simpler regimen that ultimately results in improved health outcomes and lower healthcare costs. This trial demonstrates that IDeg, titrated using either the Simple or Step-wise algorithm, leads to good glycemic control and is well tolerated, offering individualized titration regimens that best meet patient needs.
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